| Literature DB >> 32966739 |
Katja Parschat1, Sandra Schreiber1, Dirk Wartenberg1, Benedikt Engels1, Stefan Jennewein1.
Abstract
Human milk oligosaccharides (HMOs) are unique components of human breast milk. Their large-scale production by fermentation allows infant formulas to be fortified with HMOs, but current fermentation processes require lactose as a starting material, increasing the costs, bioburden, and environmental impact of manufacturing. Here we report the development of an Escherichia coli strain that produces 2'-fucosyllactose (2'-FL), the most abundant HMO, de novo using sucrose as the sole carbon source. Strain engineering required the expression of a novel glucose-accepting galactosyltransferase, overexpression of the de novo UDP-d-galactose and GDP-l-fucose pathways, the engineering of an intracellular pool of free glucose, and overexpression of a suitable α(1,2)-fucosyltransferase. The export of 2'-FL was facilitated using a sugar efflux transporter. The final production strain achieved 2'-FL yields exceeding 60 g/L after fermentation for 84 h. This efficient strategy facilitates the lactose-independent production of HMOs by fermentation, which will improve product quality and reduce the costs of manufacturing.Entities:
Keywords: 2′-fucosyllactose; fermentation; human milk oligosaccharides; lactose; metabolic engineering; sucrose; sugar efflux transporter; sugar export
Mesh:
Substances:
Year: 2020 PMID: 32966739 DOI: 10.1021/acssynbio.0c00304
Source DB: PubMed Journal: ACS Synth Biol ISSN: 2161-5063 Impact factor: 5.110